Member Info for LordSnooty

There's a job going in Snooty's Horse if you're interested....

You mean you bought HERE? I meant FDI!

we know it was our house broker Singer that took the shares at 5.5p, today's 8.5 RNS says so. It will be instructive to see if Singer has been offloading some of that buy into the market today - I am thinking that, by the time the RTO takes place, MMs generally will not want any substantial number of XEN shares on their books due to UK delisting. Hence the volumes we are currently seeing. But I must admit that's pure conjecture on my part.

As a Peer of the old school, one hesitates to go head to head with you mathematical types. However, since the ownership of XEN is remaining almost exclusively in the hands of its existing shareholders on the day the deal is done, then surely any value can be ascribed to GSL's shares? At the moment each share is an empty shell, just as at the moment the company itself is an empty shell, until such time as XEN fills them on deal day. Then each becomes worth whatever value was ascribed to it by the deal itself. As for the value of GSL, I imagine that no residual value will be ascribed to the company by deal day - the fee for the use of the shell will be in the form of 'new' Xenetic shares issued presumably to the sole remaining director, Mr Ari L Nagler, "President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director". Is one missing something?

"Xenetic Biosciences (LON:XEN) was also in favour after it said it had found a takeover candidate to give it a quick and cost-effective quote in the US. Shares rose 15% to 6.45p". http://www.proactiveinvestors.co.uk/companies/market_reports/62380/ftse-100-higher-for-eighth-day-as-europe-rally-continues-62380.html

I'm glad for you. The long path to where FDI stands today is littered with broken promises, once signal projects quietly shelved or forgotten as non-viable and fat cat director rewards for failure. Over the years there are very few investors who have profited from this company. I am one who was lucky enough to do well, but for every winner there have been many losers here, largely due to the half-truths, lack of transparency and poor strategic decision making of the company. As can be seen from my posts below, my view of FDI has not changed. If you have speculated on price movement here and won I congratulate you. As an investment I would not touch this company again myself.

is running in the background. Jimmy is taking a tyre iron to it, so it will probably be winkled out when we are safely ensconced in our comfortable, spacious and state-of-the-art new offices next door to Shire in Lexington MA.

that Jimmy's had a serious word with GAIF (General Sales & Leasing). One word. Scram.

http://www.otcmarkets.com/stock/GAIF/company-info

http://www.sec.gov/Archives/edgar/data/1534525/000125529413000825/ex9_1.htm

http://www.sec.gov/Archives/edgar/data/1534525/000125529413000825/mainbody.htm

Well done, you got lucky. Don't forget however that even if FDI somehow manages to find bank(s) to debt fund a large part of the capex needed, there will be a significant additional component that will be against future diamond sales. In addition, if the existing plant closes as mooted at the end of this year, FDI will have no revenue for at least the next two years, and any revenue after that will be impaired by repayment of loans given against future diamond sales for at least a year or two after than, even assuming they finally manage not to crush the big ones.

that GSL, the shell into which we look like reversing, has 135m shares in issue, compared to XEN's 407m. Xenetic will be issuing a few million shares to GSL as 'fees' for the service that company is providing in facilitating our transfer to the US, perhaps increasing XEN's shares in issue total to 410-420m. Therefore I think it is possible that a share consolidation of XEN shares at about 3:1 or a little more will take place before the move to the US takes place.

Given today's RNS and its contents, I'd say we are not far now from the RTO taking place and acquiring a new home Stateside.

trial results are due in the next couple of months. As reported so far for Ph I, no ill effects and no maximum dosage.

is offloading not buying.

this stock is almost entirely at the mercy of the MMs; there is very little retail buying and selling. That being the case, these odd double digit trades appear from time to time, and some of our more conspiratorial friends believe they signal something or other. As an old Peer with many years experience, I hold no opinion either way - one could say I take a XEN attitude to such phenomena..

Read this: http://www.lse.co.uk/share-regulatory-news.asp?shareprice=XEN&ArticleCode=5ytzt0ha&ArticleHeadline=Rule_24_Announcement. In particular this paragraph: "Xenetic's plan is for it to be acquired on a share-for-share basis by a US Counterparty, where the level of effective dilution to Xenetic's shareholders is modest and agreed in advance. This means that, other than for an acceptable level of dilution (which is deemed to be the "cost" of achieving Xenetic's aims) and the fees and costs of the Possible Offer, the entity formed by the completion of the Possible Offer will be as near as possible the same entity as Xenetic, with the same assets and liabilities, save that it would have a new US holding company."

We don't know the price yet but we can expect to know soon, given that today's RNS details who we are in negotiations with, and that we are in negotiations exclusively with them. However, the big bonus will come to those capable of holding until we are listed in the US and are receiving results from our drug candidates, the first of which is likely to be OncoHist. So be of good faith and hold, unless of course you wish to sell to Snooty at this bargain basement price, in gratitude for the priceless advice that he has provided over the months and years.

yes, this is a reverse take over; as detailed in the July RNS, we are reversing into a shell whereby all of us will hold exactly the same number of shares as before (as of the RTO), but with a small number of shares issued in addition to the shell company as a fee for their services. We don't yet know the price at which the RTO will take place, but at a guess I would say a decent premium to where we are today, with the added bonus that we are waiting on several pieces of news, including trial results for OncoHist.